A plasma-derived haptoglobin, available commercially in Japan, has been used to treat severe hemolysis during blood transfusions, extracorporeal circulation, and thermal injury, and limited evidence suggests that haptoglobin administration during cardiopulmonary bypass can reduce postoperative AKI [109, 110]. The gene discussed is HP; the disease is acute kidney injury.